Skip to content
Ashvattha Therapeutics
Ashvattha Therapeutics
  • Home
  • About Us
    • Senior Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • D6-B483
    • OP-801
    • D-4517.2
    • OP-101
  • News
  • Careers
  • Contact
Ashvattha Therapeutics
  • Home
  • About Us
    • Senior Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • D6-B483
    • OP-801
    • D-4517.2
    • OP-101
  • News
  • Careers
  • Contact

Month: August 2020

Ashvattha Therapeutics Subsidiary Orpheris Enrolls First Patients in Phase 2 PRANA Clinical Study Evaluating OP-101 for Severe COVID-19

November 12, 2020August 31, 2020 by ashvatthaadmin

Orpheris, a subsidiary of Ashvattha, announced enrollment of the first patients in its multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hospitalized adults with severe COVID-19.

Categories Press Release Leave a comment

Recent Posts

  • Ashvattha Therapeutics Announces Preclinical Data at the 2022 Alzheimer’s Association International Conference (AAIC) Demonstrating its Hydroxyl Dendrimer-Based Imaging Agent [18F]OP-801 Can Detect Early-Stage Neuroinflammation with a Higher Sensitivity Than TSPO-PET
  • Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical Trial for OP-101 in Severe COVID-19 Showing Significant Reduction in Inflammatory and Neuroinflammatory Markers and Improved Clinical Outcomes
  • Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 Alzheimer’s Association International Conference (AAIC)
  • Ashvattha Therapeutics Announces Presentation of Preclinical Data at the 2022 Neurofibromatosis (NF) Conference Demonstrating the Potential of Hydroxyl Dendrimer Therapeutics to Reduce Toxicity in Targeted Treatment of Plexiform Neurofibroma
  • Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based Therapeutics at the 2022 Neurofibromatosis (NF) Conference

Recent Comments

    Archives

    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • September 2021
    • June 2021
    • May 2021
    • April 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • June 2020
    • May 2020

    Categories

    • In the News
    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Howdy, this is Creativo

    We just added a brand new Off Canvas Sidebar. You can change the content you see here by going to Appearance -> Widgets -> Off Canvas Sidebar.

    Of course you can also change the design of this sidebar by going to Appearance -> Theme Options -> Off Canvas Sidebar.

    Change everything from: background color, font color, font size, sidebar headings and more.

    © Copyright 2022 Ashvattha Therapeutics.
    • Privacy Policy
    © 2022 Ashvattha Therapeutics • Built with GeneratePress